Botanix Pharmaceuticals (ASX:BOT) said that the commercial launch of its lead dermatology product, Sofdra, a topical gel for treating excessive underarm sweating, remains "on track," according to a Monday filing with the Australian bourse.
The company's sales team is performing in line with expectations, and the full digital launch expected this month will further drive prescription volume, per the filing.
Growth in new patient prescriptions is also on track, with refill rates exceeding targets, the filing added.
The company also said it does not expect any material impact from tariffs on Sofdra.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.